Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming Group N.V (PHAR) Convertible Debt: 2020-2023

Historic Convertible Debt for Pharming Group N.V (PHAR) over the last 4 years, with Dec 2023 value amounting to $136.6 million.

  • Pharming Group N.V's Convertible Debt rose 1.13% to $93.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $93.1 million, marking a year-over-year increase of 1.13%. This contributed to the annual value of $136.6 million for FY2023, which is 3.78% up from last year.
  • Pharming Group N.V's Convertible Debt amounted to $136.6 million in FY2023, which was up 3.78% from $131.6 million recorded in FY2022.
  • In the past 5 years, Pharming Group N.V's Convertible Debt ranged from a high of $139.0 million in FY2021 and a low of $149,727 during FY2020.
  • Moreover, its 3-year median value for Convertible Debt was $136.6 million (2023), whereas its average is $135.7 million.
  • Its Convertible Debt has fluctuated over the past 5 years, first spiked by 92,740.30% in 2021, then declined by 5.32% in 2022.
  • Pharming Group N.V's Convertible Debt (Yearly) stood at $149,727 in 2020, then spiked by 92,740.30% to $139.0 million in 2021, then dropped by 5.32% to $131.6 million in 2022, then increased by 3.78% to $136.6 million in 2023.